The Impact of Mobile Health Use on the Self-care of Patients With Type 2 Diabetes: Protocol for a Randomized Controlled Trial.
diabetes
disease management
mobile application
self-care
Journal
JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504
Informations de publication
Date de publication:
17 Jun 2022
17 Jun 2022
Historique:
received:
30
08
2021
accepted:
29
03
2022
revised:
04
03
2022
entrez:
17
6
2022
pubmed:
18
6
2022
medline:
18
6
2022
Statut:
epublish
Résumé
Chronic diseases are a substantial public health issue worldwide and affect an individual's quality of life. Due to the alarming rise in type 2 diabetes, health care that was primarily focused on diagnosis and treatment of the disease is increasingly focused on prevention and self-care. Patients who adhere to a constant and strict treatment regimen (physical activity, diet, medication) and regularly monitor their health are more likely to maintain self-care and health, prevent the exacerbation of the disease, and avoid the complications of diabetes (retinopathy, diabetic feet, etc). In recent years, many innovative devices that have become increasingly present in inpatient health care, such as mobile apps, are available to help patients maintain consistency in monitoring their health status. Mobile apps make it easier for individuals to monitor their self-care and illness and follow instructions regarding disease control. This study aims to determine the impact of mobile app use on self-care in patients with type 2 diabetes. We will evaluate and test the usefulness of the forDiabetes app as a tool to improve the self-care of individuals with type 2 diabetes. We will perform a double-blind randomized controlled trial. The study will include individuals aged over 18 years diagnosed with or have regulated type 2 diabetes who are treated in family medicine practices. Additionally, the individuals included in the study should not have any acute complications due to the consequences of type 2 diabetes. They will use an Android or iOS mobile phone and a blood glucose meter during the investigation. With the help of simple randomization, individuals will be divided into the intervention and control groups. Individuals in the intervention group will use the forDiabetes mobile app to monitor their self-care for type 2 diabetes. Individuals in the control group will not receive a particular intervention. Data will be collected using the Self-care of Diabetes Inventory questionnaire and Brief Illness Perception Questionnaire. Blood sugar, blood pressure, glycated hemoglobin (HbA In the first half of 2020, we have prepared a translation of the mobile app that will be used by the participants of the intervention group, as well as more detailed instructions for using the app. We have also prepared a translation of the questionnaires in Slovene. The research results will be published in 2023. This research contributes to greater visibility and usability of mobile apps for the self-care of patients with type 2 diabetes and raises awareness of the possible use of innovative methods. Clinicaltrials.gov NCT04999189; https://clinicaltrials.gov/ct2/show/NCT04999189. PRR1-10.2196/31652.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic diseases are a substantial public health issue worldwide and affect an individual's quality of life. Due to the alarming rise in type 2 diabetes, health care that was primarily focused on diagnosis and treatment of the disease is increasingly focused on prevention and self-care. Patients who adhere to a constant and strict treatment regimen (physical activity, diet, medication) and regularly monitor their health are more likely to maintain self-care and health, prevent the exacerbation of the disease, and avoid the complications of diabetes (retinopathy, diabetic feet, etc). In recent years, many innovative devices that have become increasingly present in inpatient health care, such as mobile apps, are available to help patients maintain consistency in monitoring their health status. Mobile apps make it easier for individuals to monitor their self-care and illness and follow instructions regarding disease control.
OBJECTIVE
OBJECTIVE
This study aims to determine the impact of mobile app use on self-care in patients with type 2 diabetes. We will evaluate and test the usefulness of the forDiabetes app as a tool to improve the self-care of individuals with type 2 diabetes.
METHODS
METHODS
We will perform a double-blind randomized controlled trial. The study will include individuals aged over 18 years diagnosed with or have regulated type 2 diabetes who are treated in family medicine practices. Additionally, the individuals included in the study should not have any acute complications due to the consequences of type 2 diabetes. They will use an Android or iOS mobile phone and a blood glucose meter during the investigation. With the help of simple randomization, individuals will be divided into the intervention and control groups. Individuals in the intervention group will use the forDiabetes mobile app to monitor their self-care for type 2 diabetes. Individuals in the control group will not receive a particular intervention. Data will be collected using the Self-care of Diabetes Inventory questionnaire and Brief Illness Perception Questionnaire. Blood sugar, blood pressure, glycated hemoglobin (HbA
RESULTS
RESULTS
In the first half of 2020, we have prepared a translation of the mobile app that will be used by the participants of the intervention group, as well as more detailed instructions for using the app. We have also prepared a translation of the questionnaires in Slovene. The research results will be published in 2023.
CONCLUSIONS
CONCLUSIONS
This research contributes to greater visibility and usability of mobile apps for the self-care of patients with type 2 diabetes and raises awareness of the possible use of innovative methods.
TRIAL REGISTRATION
BACKGROUND
Clinicaltrials.gov NCT04999189; https://clinicaltrials.gov/ct2/show/NCT04999189.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
UNASSIGNED
PRR1-10.2196/31652.
Identifiants
pubmed: 35713944
pii: v11i6e31652
doi: 10.2196/31652
pmc: PMC9250066
doi:
Banques de données
ClinicalTrials.gov
['NCT04999189']
Types de publication
Journal Article
Langues
eng
Pagination
e31652Informations de copyright
©Lucija Gosak, Majda Pajnkihar, Gregor Stiglic. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 17.06.2022.
Références
Ther Adv Endocrinol Metab. 2019 Jan 28;10:2042018818824215
pubmed: 30728941
Saudi J Anaesth. 2017 May;11(Suppl 1):S80-S89
pubmed: 28616007
Adv Nutr. 2017 May 15;8(3):449-462
pubmed: 28507010
JMIR Mhealth Uhealth. 2014 Dec 11;2(4):e52
pubmed: 25499592
Diabetes Care. 2020 Jan;43(1):250-260
pubmed: 31806649
JMIR Mhealth Uhealth. 2017 Dec 19;5(12):e197
pubmed: 29258981
Eur J Prev Cardiol. 2019 Dec;26(2_suppl):55-63
pubmed: 31766913
Diabetes Ther. 2020 Mar;11(3):607-619
pubmed: 31983028
JMIR Mhealth Uhealth. 2020 Jul 8;8(7):e16365
pubmed: 32673235
Diabetes Res Clin Pract. 2014 Nov;106(2):390-2
pubmed: 25484069
J Med Internet Res. 2019 Apr 09;21(4):e12541
pubmed: 30964439
World J Diabetes. 2018 Dec 15;9(12):209-219
pubmed: 30588282
J Hum Reprod Sci. 2011 Jan;4(1):8-11
pubmed: 21772732
Int J Health Plann Manage. 2019 Jul;34(3):1025-1035
pubmed: 31368137
BMC Public Health. 2018 Jan 10;18(1):119
pubmed: 29316905
J Diabetes Sci Technol. 2017 Sep;11(5):1015-1027
pubmed: 28560898
Int J Nurs Stud. 2021 Apr;116:103383
pubmed: 31353026
ANS Adv Nurs Sci. 2012 Jul-Sep;35(3):194-204
pubmed: 22739426
Patient Prefer Adherence. 2018 Jun 06;12:963-970
pubmed: 29922042
J Diabetes Metab Disord. 2019 Jul 12;18(2):307-313
pubmed: 31890655
Niger Med J. 2017 May-Jun;58(3):107-113
pubmed: 29962652
BMC Endocr Disord. 2017 Oct 16;17(1):66
pubmed: 29037177
J Med Internet Res. 2017 Jun 23;19(6):e227
pubmed: 28645890
Malays J Med Sci. 2018 Nov;25(6):85-99
pubmed: 30914882
JMIR Mhealth Uhealth. 2020 Mar 2;8(3):e16665
pubmed: 32130184
Interact J Med Res. 2012 Oct 04;1(2):e8
pubmed: 23612026
J Gen Intern Med. 2018 Jul;33(7):1167-1176
pubmed: 29740786
JMIR Mhealth Uhealth. 2019 Apr 24;7(4):e13204
pubmed: 31017586
Lancet. 2002 Feb 16;359(9306):614-8
pubmed: 11867132
J Clin Med. 2020 Jul 03;9(7):
pubmed: 32635196
J Psychosom Res. 2006 Jun;60(6):631-7
pubmed: 16731240
Diabetologia. 2019 Jun;62(6):877-887
pubmed: 30963188
JMIR Mhealth Uhealth. 2020 Mar 6;8(3):e17455
pubmed: 32141838
J Med Internet Res. 2015 Feb 24;17(2):e52
pubmed: 25803266
Res Nurs Health. 2007 Aug;30(4):459-67
pubmed: 17654487
Sci Rep. 2020 Sep 17;10(1):15297
pubmed: 32943657
PLoS One. 2019 Jun 5;14(6):e0217771
pubmed: 31166971
JMIR Mhealth Uhealth. 2018 May 23;6(5):e126
pubmed: 29792290
Indian Dermatol Online J. 2019 Aug 28;10(5):601-605
pubmed: 31544090
JMIR Mhealth Uhealth. 2016 Jun 10;4(2):e72
pubmed: 27287964
BMJ Open. 2019 Jun 25;9(6):e025714
pubmed: 31243029
Diabetes Technol Ther. 2017 Dec;19(12):730-738
pubmed: 29028442
Res Nurs Health. 2006 Oct;29(5):489-97
pubmed: 16977646
J Clin Nurs. 2014 Feb;23(3-4):541-9
pubmed: 23789978
Am J Public Health. 2014 Aug;104(8):e25-31
pubmed: 24922170
JMIR Mhealth Uhealth. 2017 Mar 01;5(3):e4
pubmed: 28249834